Lymphopenic infectious mononucleosis.
Lymphopenic IM is a real phenomenon. It is likely to appear as a more severe clinical illness and, in contrast to the benign course to typical IM, may have a poorer prognosis. The clinical spectrum of IM should be extended to included to include lymphopenic patients if their diagnosis is supported by appropriate heterophil and EBV antibody titers.
D058186:Acute Kidney Injury / Q000150:complications / Q000188:drug therapy; D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001639:Bicarbonates / Q000627:therapeutic use; D004071:Digitalis Glycosides / Q000627:therapeutic use; D005260:Female; D006505:Hepatitis / Q000150:complications / Q000188:drug therapy; D006801:Humans; D007231:Infant, Newborn; D007244:Infectious Mononucleosis / Q000150:complications* / Q000188:drug therapy; D007328:Insulin / Q000627:therapeutic use; D008231:Lymphopenia / Q000150:complications*; D008297:Male; D009205:Myocarditis / Q000150:complications / Q000188:drug therapy; D010102:Oxygen Inhalation Therapy; D010195:Pancreatitis / Q000150:complications / Q000188:drug therapy; D011241:Prednisone / Q000627:therapeutic use; D012772:Shock, Septic / Q000150:complications
D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents; D001639:Bicarbonates; D004071:Digitalis Glycosides; D007328:Insulin; D011241:Prednisone